Duane Smyth
Optometrist · Pittsburgh, PANPI 1851375018
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 237 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,897, 2.7 times the $701 reported in 2019. Among optometrist clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 237 payments — averaging $23.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$817
- Regeneron Healthcare Solutions, Inc.$559
- Tarsus Pharmaceuticals, Inc.$558
- Alcon$523
- Sun Pharmaceutical Industries Inc.$410
- Novartis$365
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,634100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 32 | $817 |
| Regeneron Healthcare Solutions, Inc. | 20 | $559 |
| Tarsus Pharmaceuticals, Inc. | 21 | $558 |
| Alcon | 18 | $523 |
| Sun Pharmaceutical Industries Inc. | 18 | $410 |
| Novartis | 29 | $365 |
| AbbVie(2 entities) | 8 | $283 |
| Oyster Point Pharma, Inc. | 16 | $281 |
| Aerie Pharmaceuticals, Inc. | 12 | $227 |
| NEW World Medical,inc. | 1 | $192 |
| Glaukos Corporation | 4 | $165 |
| Dompe US, Inc. | 5 | $127 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $118 |
| Sanofi | 1 | $105 |
| Spark Therapeutics, Inc. | 1 | $104 |
| Eyevance Pharmaceuticals LLC | 7 | $93 |
| Harrow Eye, LLC | 4 | $87 |
| Genentech USA, Inc. | 3 | $65 |
| Rxsight Inc | 3 | $64 |
| Shire North American Group Inc | 3 | $52 |
| Biotissue Holdings Inc. | 3 | $50 |
| Coopervision Inc. | 1 | $49 |
| Rayner Intraocular Lenses Limited | 3 | $47 |
| Apellis Pharmaceuticals, Inc. | 3 | $46 |
| Thea Pharma Inc. | 2 | $40 |
| Astellas Pharma US Inc | 1 | $35 |
| Lombart Brothers, Inc. | 2 | $32 |
| Recordati_rare_diseases_inc. | 1 | $23 |
| Vyera Pharmaceuticals, LLC | 1 | $21 |
| Coherus Oncology, Inc. | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Leadiant Biosciences, Inc. | 1 | $15 |
| Akorn, Inc. | 1 | $15 |
| Dutch Ophthalmic, USA | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$247
- XIIDRA$247
- Kahook Dual Blade$192
- Clearpath$192
- Ahmed Glaucoma Valve$192
- Streamline$192
- Via360$192
- VYZULTA$138
- VUITY$125
- Precision7$120
- XDEMVY$120
- ALDURAZYME$105
- CEREZYME$105
- FABRAZYME$105
- CERDELGA$105
- LUMIZYME$105
- LUXTURNA$104
How this compares
$5,634 in reported general payments places this provider in the 95th percentile of 2,165 optometrist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 21 | $226 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Pittsburgh
- Erick HendersonPittsburgh$266K
- William Vincett JrPittsburgh$57K
- Mark ClementPittsburgh$11K
- Jane ManlyPittsburgh$9K
- James DeomHazle Township$793K
- Gregory CaldwellDuncansville$547K
- Leslie O DellNew Freedom$388K
- Kevin BistlinePlymouth Meeting$302K
- Thomas KislanStroudsburg$266K
- Ryan YealyLancaster$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.